September 2016 - Evolution Biotechnologies
archive,date,ajax_fade,page_not_loaded,,qode-title-hidden,qode-theme-ver-16.4,qode-theme-bridge,wpb-js-composer js-comp-ver-5.4.7,vc_responsive

Bedford, UK, and Austin, Texas; September 14th 2016 ­Evolution Biotechnologies (, the company working to expand the use of biological control into medically important areas, today announces a presentation by its Chief Officer, Dr. David Harper. The presentation, entitled “Bacteriophages as Biological Control Agents” is to be given on Friday 16th September at the conference on “Phage-based Technologies Against Antimicrobial Resistance” organised under the EU FP7 EVOPROG programme, in Stratford-upon-Avon, UK. About Evolution Biotechnologies Evolution Biotechnologies (UK company 09473027 / US company 6050853) has been established to extend the application of biological control from its agricultural roots into areas of biomedical importance. The company’s...